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METHOD FOR ENHANCING PROTECTIVE
CELLULAR RESPONSES TO GENOTOXIC
STRESS IN SKIN

immune responses at the epidermal level involving Langer

hans cells, keratinocytes, cytokines, polynuclear cells,
endothelial cells, mast cells, and lymphocytes.

Structurally, the skin comprises epithelial tissue (the

CROSS REFERENCE TO RELATED
APPLICATIONS

epidermis) in the outer layer and beneath it, connective

This application claims bene?t of provisional patent
application serial No. 60/110,482 ?led Dec. 1, 1998. The
entire disclosure of provisional patent application serial No.

erates every four to six Weeks. Its primary function is to

60/110,482 is hereby incorporated by reference.

tissue (the dermis), and beneath that, the fatty tissue
(hypodermis). The epidermis is not vasculariZed and regen
10

BACKGROUND

1. Field of the Invention
The invention is directed to methods and composition of

using organic molecules termed pro-NAD agents capable of

functions by providing strength, support, blood, and oxygen
to the skin. The principal cell components of the dermis are
15

blood supply to the dermis for regeneration.

responses to genotoxic stress in skin.

The mechanisms of skin deterioration involve a gradual
20

factors that contribute to skin aging include toxic metabolic

25

loss of moisture, ?ne lines, deep lines, Wrinkles, and loss of

30

shoWn to be a contributing factor. Under the somatic muta

tion theory, cells gradually lose their youthful characteristics

elasticity as Well as atrophic sclerosis and other blemishes of

prolonged exposure to internal and external factors. Internal
deterioration factors include natural metabolic byproducts
35

External deterioration factors include ioniZing radiation

and their capacity to divide by the accumulation of muta
tions (errors) in their genetic code. These mutations may be
caused by free radicals or alkylating agents generated in
metabolism that lead to unrepaired DNA damage. Over time,
mutations accumulate in the body until the cell can no longer
divide or produce functional proteins.
External factors such as chemical and physical agents in
the environment can also cause DNA damage that leads to

such as sunlight and chemical insults such as pollution and
cigarette smoke. In theory, skin care methods and compo
sitions should inhibit, or sloW the process of skin deterio
40

skin deterioration. The external factors include sunlight,
pollution, and ingested chemicals from smoking or from
food.
Deterioration of skin leads to changes in dermal thickness

and elasticity due to increased crosslinking of collagen.
Epidermal regeneration increases in activity While

care are generally reactive rather than proactive. That is,
current methods and compositions reduce or obscure the
signs of aging but have minimal or no effect on the under

lying progressive and cumulative biochemical processes that

tion. The consequences of internal deterioration can be
observed over the entire body from the skin to the internal
organs. While the mechanisms of internal deterioration are

not completely understood, somatic mutation has been

skin. Skin deteriorates With age as a natural consequence of

ration by counteracting these internal and external factors.
Unfortunately, current methods and compositions for skin

and progressive process that begins from birth. Internal

byproducts, autoimmune diseases, and genetic predisposi

enhancing natural protective responses of skin cells to DNA
damage. The methods and compositions are effective for the
prevention and treatment of skin deterioration that results
from DNA damage to cells of the skin. The symptoms of
such skin deterioration are many and typically include the

such as free radicals Which cause the aging of all tissues.

?broblasts although it also contains sWeat glands, sebaceous
glands, hair follicles, and small fat cells. Hypodermis, also
knoWn as the super?cial fascia, attaches the dermis to the
underlaying structures. Its function is to promote an ongoing

enhancing dermal and epidermal skin cell NAD content With
a resulting enhancement of DNA repair and other protective

2. Description of the Background
The present application relates to methods and composi
tions capable of modulating and upregulating the cellular
nicotinamide-adenine-dinucleotide (NAD) content by the
topical application of chemical agents for the purpose of

maintain the body’s skin integrity, acting as a physical
barrier to toxic agents, dirt, bacteria, microorganisms, and
physical insults. The dermis is beneath the epidermis and

45

cause skin deterioration. It is therefore desirable to have a

skin care method and composition Which not only reduce the
symptoms of deterioration but also treat the underlying

metabolism, sWeat glands, and vasculariZation, all decrease
in activity. The damage from internal and external factors is
progressive and cumulative and results in the appearance of
deterioration associated With aged skin.
Related to the somatic mutation theory, both internal and

causes of skin deterioration in such a Way that deterioration

external factors contribute to oxidative stress, Which in turn

can actually be retarded. To understand the limitations of
current methods and compositions, it is necessary to under
stand the function and structure of the skin and the mecha
nisms of skin deterioration.

results in DNA damage. In humans, oxidative stress and
DNA damage is caused by factors such as hyperbaric
oxygen, gamma radiation, ultraviolet radiation, oZone,

At ten pounds, the skin is the largest organ in the body.
FIG. 1 shoWs a diagram of skin marking the location of the

peroxides, free radicals, alkylating agents, and redox cycling
55

avoiding sunlight, they cannot be eliminated. Some factors

tWo major cell types present in skin, namely ?broblasts
located in the dermal layer of the skin and keratinocytes
located in the epidermal layer of the skin. The skin provides

like ioniZing radiation are present in all environments at a
loW level and other factors are byproducts of metabolism

the ?rst line of defense betWeen the body’s interior and

harmful environmental insults by Well established physical
and biochemical mechanisms. Physical protection mecha
nisms include the relatively impermeable barrier the skin

60

the skin maybe damaged, the underlying tissue is preserved.

immune systems. Microbiological pathogens are repelled by

and cannot be totally eliminated. Further, urban environ
ments have high levels of ground level pollution from a
variety of sources that are not likely to be reduced in the near

future. HoWever, While DNA damage cannot be avoided, not
all DNA damage leads to mutations.
DNA damage does not necessarily lead to mutation

provides. The skin can, to some extent, repel and absorb
insults such as chemicals and ultraviolet light so that While

Biochemical mechanisms include the innate and acquired

drugs. While total oxidative stress and DNA damage may be
reduced by living in a loW pollution environment and

65

because a normal cell contains diverse and effective systems

for repairing damaged DNA. There are at least 50, and
possibly more than 100 genes involved in DNA repair. The

US 6,337,065 B1
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importance of good DNA repair in retarding skin deteriora

mental insults. That is, a sunblock With an SPF factor of 15

tion is most noticeable in patients that suffer from DNA
repair defects such as xeroderma pigmentosum
XP

Will not reduce photoaging 15 fold. There is also a danger

have early and accelerated skin deterioration, clearly dem
onstrating the importance of DNA repair to reducing dete

age and contribute to skin deterioration. Finally, every major
class of sunblock has been linked to skin allergies.
Finally, there are agents that are physical blends of

that chemicals in some sunblocks Will increase DNA dam

rioration of the skin. In addition to DNA repair, a normal cell

also has systems that invoke “programmed cell death” by a
process termed apoptosis. The process of apoptosis effec

existing agents. Aphysical blend is a mixture of tWo or more

chemicals. Physical blends can be mixed poWders, mixed

tively “erases” cells damaged beyond the point of repair.

solutions, mixed emulsions, mixed colloidal solutions, par
ticles in solutions, and the like. An example of a physical

These natural defense mechanisms of the skin have been

ignored by current methods of preventing skin deterioration.
Many creams, lotions, bath oils, ointments, pastes,
cleansers, covers, and poWders claim to be effective in
preventing skin deterioration. HoWever, all current methods
and compositions have severe disadvantages in that they are

blend may be a covering or coloring cosmetic mixed With a

sunblock (titanium dioxide) and a hydroxy acid.
In summary, current methods of skin treatment are mostly
15

limited in their ability to retard skin deterioration. Most over
the counter skin care products soften deteriorated skin or
otherWise reduce the symptoms of deteriorated skin With no
effect on the underlying biochemical processes involved in

reverse damage to the dermal tissue. There is a need for

topical skin care products that are proactive rather than
reactive. A proactive product is one that Will assist the skin

in resisting DNA damage by either preventing damage or
assisting in repair of any damage.

deterioration. Many existing skin care products and cosmet

ics function by providing moisture to the skin, preventing
moisture loss, or providing cover to obscure the visible signs
of deterioration. While traditional cosmetics may have

SUMMARY OF THE INVENTION

effects on appearance, these effects are evanescent and any

apparent improvement disappears as soon as the product use

reactive in that they treat the symptoms of deterioration after
the damage is done. Current skin treatment methods do not

25

The present invention overcomes many of the limitations,
problems and disadvantages associated With current strate

is discontinued. Further, traditional cosmetics’ effectiveness

gies and designs for preventing skin deterioration and pro

decrease upon exposure to moisture and thus cosmetics must

vides methods and composition for the treatment of skin
deterioration.
One object of the invention is directed to a method and
composition for treating skin to prevent and sloW the dete
rioration process.
It is another objective of the invention to provide a

be reapplied after exercise, sWimming, or any other expo
sure to moisture. Some cosmetics contain metals (e.g., iron

and copper) Which may actually increase skin levels of free
radical formation and possibly promote deterioration. As the
use of such products does not prevent deterioration, more
and more of the product is needed as time progresses to

obscure the increasing severe condition of the underlying
skin.
Another method for treating aging skin is the use of alpha

35

hydroxy acids (AHA) such as lactic acid, citric acid, glycolic
acid, malic acids; beta hydroxy acids (BHA) such as sali

Another object of the invention is directed to a compo
sition for topical application comprising one or more pro

cylic acid; and retinoids (e.g. tretinoin (retin A), retinol and

NAD agent that promote cellular DNA repair.

retinal), as exfoliants. These agents help remove the upper
most layer of skin to expose the more youthful underlying
skin. HoWever, there is a danger that by removing the outer

One embodiment of the invention is directed to a phar
maceutical composition for a subject in need of an elevation
of intracellular NAD content. The pharmaceutical compo

layer of skin, AHA, BHA and retinoids can compromise the
important barrier function of skin. It is possible that the use

of these exfoliants may accelerate skin aging by removing
the protective outer layer of skin. Exfoliants and other
ingredients may also increase the skin’s sensitivity to envi
ronmental conditions such as sunlight, Wind, cold tempera

method to retard deterioration of the skin by enhancing the
skin’s natural DNA repair mechanism.
It is another object of the invention to provide a method
for the sustained release of pro-NAD agents to skin cells.

sition comprises a pro-NAD agent and a pharmaceutically
45

acceptable carrier. The pro-NAD agent is present in the
pharmaceutical composition at a concentration sufficient to

elevate intracellular NAD in the subject. The pharmaceutical
composition may be adapted for topical administration to the
skin. Adaptation may included the inclusion of a pharma
ceutically acceptable carrier Which is suitable for use in

ture and dry air, or to chemical agents such as antigens, or
may exacerbate the irritation attributable to a pre-existing

topical applications.

skin disease. Another disadvantage of AHA, BHA and
retinoids is that these compounds are potential skin irritants

The pro-NAD agents of the invention may comprise one
or more compounds With the folloWing formula:

Which can induce side effects such as sore, red skin.

Another popular method for skin treatment is the use of

sunblocks. Sunblock (i.e., sunscreen) refers to any chemical

55

that When applied to the skin, reduces the amount of UV

light that reaches the skin. By preventing UV absorptions
that cause genomic mutations, sunblocks can decrease and
retard skin deterioration. Sunblocks Were originally

designed to prevent sunburn (also knoWn as erythema), an
acute reaction to overexposure to the sun. The strength of

sunblocks is measured by the SPF index (Sun Protection
Factor). An SPF value of 15, for example, Will provide 15
times the protection of bare skin to sunburns. HoWever, it
should be noted that the SPF values, Which measures resis
tance to sunburn, cannot be extrapolated to photoaging

protection, Which is caused by constant loW level environ

Where R1 is a hydrogen or any chemical group that can be

65

enZymatically or chemically removed to generate nicotinic
acid folloWing administration to said subject. A chemical
group is any chemical molecule such as, for example, any
branched or unbranched (straight) alkane, alkene, or alkyne
group. In a preferred embodiment, the chemical group is a

US 6,337,065 B1
5

6

group such as an ester, that can be removed by an esterase

agent is betWeen about 0.01% and about 3% by Weight. The
pharmaceutical composition may further comprise an
optional agent such as, for example, antioxidants,

following the administration of the pharmaceutical compo
sition to the subject. Preferably, the esterase is an intracel
lular esterase such that the chemical group is not removed
until the pro-NAD agent is inside a cell.
In a preferred embodiment, R1 is an unbranched or
branched chain alkane, alkene or alkyne of 1 carbon to about
30 carbon atoms, such as, for example betWeen about 14 and
about 22 carbons. R1 may also contain one or more func
tional groups. A functional group is an atom or group of

atoms acting as a unit, that has replaced a hydrogen atom in
a hydrocarbon molecule and Whose presence imparts char
acteristic properties to a molecule. Examples of functional

sunscreens, vitamins, a pH stabiliZer, or a combination of

these agents.
It is understood that the pharmaceutical composition of
the invention may be used for treating a subject. The subject
is an animal. The animal may be a unicellular or a multi
10

Another embodiment of the invention is directed to a

method for treating or for sloWing skin deterioration. In the
method, a pharmaceutical composition of the invention may
15 be administered to a subject to treat, sloW or reverse skin

deterioration in the subject. Preferably, the method Will

ethers, sul?de, halide, nitro, nitroso, aZides, diaZo, and a
combination of these groups.
In a preferred embodiment, R1 may be a chemical group

that changes the log PO/W of said pro-NAD agent to betWeen
about 5 to about 20.

In a preferred embodiment, the pro-NAD agent has a log
PO/W range betWeen about 5 to about 20. More preferably, the
pro-NAD agent has a log PO/W range betWeen about 10 to
about 15.

For example, the pro-NAD agent may be

20

25

methylnicotinate, ethylnicotinate, butylnicotinate,

Another embodiment of the invention is directed to a
30

agent. In the process, an effective amount of a topical
composition comprising an effective amount of one or more

pro-NAD agent is applied to the skin of a subject. The
pro-NAD agent used in this process may be any pro-NAD

ethylnicotinate, butylnicotinate, hexylnicotinate, octylnico
tinate and at least one chemical selected from the group

agent discussed in this application.

consisting of tetradecylnicotinate and octadecylnicotinate.
Alternatively, the pro-NAD agent may comprise one or
more compounds With the folloWing formula:

via dermal patch or sloW release mechanism to the layer of
skin of the mammal. In addition, the administration may be
oral or parenteral.

process for achieving transdermal delivery of a pro-NAD

decylnicotinate or a combination of these chemicals. A

selected from the group consisting of methylnicotinate,

increase the skin cell intracellular NAD concentration by at
least about 50% over an untreated subject. More preferably,
the method Will increase the intracellular NAD concentra
tion by an even greater amount such as, for example, by
100% over an untreated subject. It is understood that skin
cell in this application refers to ?broblasts and/or kerati

nocytes. The administration may be applied topically, intra
dermally or subcutaneously. Topical administration may be

hexylnicotinate, octylnicotinate, tetradecylnicotinate, octa
combination may be, for example, at least one chemical

cultured cell population, a cultured cell line, an egg, a sperm
or a Zygote.

groups that can be used include thiol, alcohol, amine,

carboxylic acid, onium, carboxylic anhydride, carboxylic
ester, acyl halide, amide, nitrile, aldehyde, ketone, imines,

cellular animal such as, for example, a mammal. Further, the
mammal may be a human. The subject may also be a

Another embodiment of the invention is directed to a
35

process for reducing the cytotoxic effects of DNA damage in
the skin of a mammal by enhancing or elevating one or more
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skin cell intracellular proteins. The skin cells are the ?bro
blasts and/or keratinocytes in the skin. The process com
prises applying to a layer of skin of the mammal an effective
amount of a pharmaceutical composition of the invention.

The intracellular protein may be p53. Alternatively, the
intracellular protein may be PARP-1, PARP-2, PARP-3,
tankyrase, V-PARP and telomerase.
Another embodiment of the invention is directed to a
Where R2 is a hydrogen or a chemical group that can be 45 method for treating skin in order to inhibit skin deterioration

enZymatically or chemically removed to generate nicotina
mide after the pharmaceutical composition is administered.
For example, R2 may be a carboxylic acid containing an
alkane, alkene or alkyne of about 1 to about 30 carbon
atoms. Preferably, R2 is a carboxylic acid containing an

due to UV exposure. In the method, a pharmaceutical
composition of the invention is applied to the skin at a time
sufficiently close to the time of UV exposure to inhibit
UV-induced damage to the skin. The pharmaceutical com
50

position may be applied before UV exposure. Alternatively,

alkane R group With betWeen 14 and 22 carbons. In addition

the pharmaceutical composition maybe applied after UV

R2 also contains one or more functional groups. The func
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exposure. The time of application may be for example, less
than 1 hour, less than 2 hour, less than 6 hour, less than 12
hour or less than 1 day before UV exposure. Alternatively,
the time of application may be, for example, less than 5
minutes, less than 10 minutes, less than 20 minutes, less than
1 hour, less than 2 hours, less than 6 hours, less than 12
hours, less than 1 day, less than 2 days, or less than 5 days
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after UV exposure.
Other embodiments and advantages of the invention are

tional group may be, for example, thiol, alcohol, amine,

carboxylic acid, onium, carboxylic anhydride, carboxylic
ester, acyl halide, amide, nitrile, aldehyde, ketone, imines,
ethers, sul?de, halide, nitro, nitroso, aZides, or diaZo. Pre
ferred functional groups include thiol, alcohol, amine, and
carboxylic acid groups. R2 may also have more than one

functional group. Further, R2 may be any chemical group

that changes the log PO/W of said pro-NAD agent to betWeen
about 5 to about 20. Preferably, the pro-NAD agent has a log
PO/W range betWeen about 5 to about 20. More preferably, the
pro-NAD agent has a log PO/W range betWeen about 10 to
about 15.
The pharmaceutical composition of the invention may
have a pro-NAD agent concentration that is betWeen about

0.001% to about 10% by Weight. Preferably, the pro-NAD

set forth, in part, in the description Which folloWs and, in
part, Will be obvious from this description and understood by
the skilled artisan practicing this invention.
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DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts a diagram of skin marking the location of
the tWo major cell types present in skin, namely ?broblasts

